{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:01:03Z","timestamp":1790092863543,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.diagmicrobio.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T23:03:35Z","timestamp":1463180615000},"page":"449-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections"],"prefix":"10.1016","volume":"85","author":[{"given":"Javier","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryl E.","family":"Greenwood-Quaintance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of dalbavancin, alone and in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a foreign-body infection model","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0070","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb9000","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/TCRM.S46","article-title":"Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review","volume":"4","author":"Bennett","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2008.12.019","article-title":"Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)","volume":"64","author":"Biedenbach","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0045","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02368-06","article-title":"Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States","volume":"45","author":"Biedenbach","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0055","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1128\/AAC.01453-08","article-title":"Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates","volume":"53","author":"Biedenbach","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0035","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-six informational supplement M100-S26. 2016","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0025","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.03395-15","article-title":"New Gram-positive agents: The next generation of oxazolidinones and lipoglycopeptides","author":"Crotty","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0065","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jinf.2004.05.006","article-title":"Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo","volume":"50","author":"Darouiche","year":"2005","journal-title":"J Infect"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2016.05.009_bb0010","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dku247","article-title":"Epidemiology and burden of prosthetic joint infections","volume":"69","author":"Lamagni","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/AAC.06246-11","article-title":"Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective?","volume":"56","author":"Peel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2016.01.008","article-title":"In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections","volume":"85","author":"Schmidt-Malan","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2016.05.009_bb0015","doi-asserted-by":"crossref","first-page":"e01910","DOI":"10.1128\/mBio.01910-14","article-title":"Clinical characteristics and outcomes of prosthetic joint infection caused by small colony variant staphylococci","volume":"5","author":"Tande","year":"2014","journal-title":"MBio"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316301316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316301316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T01:55:35Z","timestamp":1536717335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316301316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0732889316301316"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.05.009","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}